Lin28: an emerging important oncogene connecting several aspects of cancer

Hao Wang1, Qin Zhao1, Kaiyuan Deng1

  • 1Department of General Surgery and Translational Medicine Center, Nanjing Medical University Affiliated Wuxi Second Hospital, Wuxi, 214002, Jiangsu, China.

Insights

The RNA-binding protein Lin28 regulates the let-7 tumor suppressor, impacting cell activities. Lin28 overexpression in cancer promotes proliferation and progression, suggesting therapeutic potential.

Area of Science:

  • Molecular Biology
  • Developmental Biology
  • Cancer Research

Background:

  • Lin28, an RNA-binding protein, is a key regulator in development and cellular processes.
  • Lin28 inhibits the let-7 tumor suppressor miRNA, affecting numerous downstream targets.
  • Aberrant Lin28 expression is linked to various cancers and poor patient prognoses.

Purpose of the Study:

  • To review the regulatory mechanisms of Lin28 in cancer.
  • To elucidate the multifaceted functions of Lin28 in tumorigenesis.
  • To explore the therapeutic potential of targeting Lin28 or let-7 in cancer treatment.

Main Methods:

  • Literature review of studies on Lin28 and cancer.
  • Analysis of Lin28's role in cellular processes like proliferation and metabolism.
  • Examination of Lin28's involvement in epithelial-mesenchymal transition (EMT) and cancer stem cells.

Main Results:

  • Lin28 promotes cancer progression by enhancing proliferation, glucose metabolism, EMT, and cancer stem cell populations.
  • Lin28's overexpression correlates with adverse outcomes in multiple cancer types.
  • Inhibition of Lin28 or restoration of let-7 can reverse oncogenic effects.

Conclusions:

  • Lin28 is a critical oncogene with diverse roles in cancer development and progression.
  • Targeting Lin28 or reactivating let-7 pathways presents promising therapeutic strategies for cancer treatment.
  • Further research into Lin28 regulatory networks is crucial for developing effective cancer therapies.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.0K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

3.0K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

6.1K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.9K